![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
University of Palermo |
---|---|
Information provided by: | University of Palermo |
ClinicalTrials.gov Identifier: | NCT00717782 |
Thrombosed external haemorrhoids are one of the most frequent anorectal emergencies. They are associated with swelling and intense pain. This study evaluated the efficacy and safety of an intersphincteric injection of botulinum toxin for pain relief in patients with thrombosed external haemorrhoids
Condition | Intervention | Phase |
---|---|---|
Thrombosed External Hemorrhoid |
Procedure: injection of botulinum toxin Procedure: injection of saline |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Investigator), Historical Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Randomized Clinical Trial of Botulinum Toxin Injection for Pain Relief in Patients With Thrombosed External Haemorrhoids |
Enrollment: | 30 |
Study Start Date: | January 2003 |
Study Completion Date: | January 2006 |
Primary Completion Date: | December 2005 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Patients were injected with 0·6 ml of a solution containing 30 units botulinum toxin A (Botox; Allergan, Ireland). A 27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter. |
Procedure: injection of botulinum toxin
Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
|
2: Placebo Comparator
Patients in the placebo group received a 0·6-ml injection of saline. A27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter. |
Procedure: injection of saline
Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
|
Background: Thrombosed external haemorrhoids are one of the most frequent anorectal emergencies. They are associated with swelling and intense pain. Internal sphincter hypertonicity plays a role in the aetiology of the pain. This study evaluated the efficacy and safety of an intersphincteric injection of botulinum toxin for pain relief in patients with thrombosed external haemorrhoids. Methods: Thirty patients with thrombosed external haemorrhoids who refused surgical operation were randomized into two groups. Patients received an intrasphincteric injection of either 0·6 ml saline or 0·6 ml of a solution containing 30 units botulinum toxin. Anorectal manometry was performed before treatment and 5 days afterwards.Results: After 5 days of treatment, the maximum resting pressure fell in both groups, but was significantly lower in the botulinum toxin group (P = 0·004). Pain intensity was significantly reduced within 24 h of botulinum toxin treatment (P < 0·001), but only after 1 week in the placebo group (P = 0·019). Conclusion: A single injection of botulinum toxin into the anal sphincter seems to be effective in rapidly controlling the pain associated with thrombosed external haemorrhoids, and could represent an effective conservative treatment for this •condition.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria :
Responsible Party: | University of Palermo ( Gaetano Di Vita ) |
Study ID Numbers: | UNIPA001 |
Study First Received: | July 16, 2008 |
Last Updated: | July 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00717782 |
Health Authority: | Italy: Ethics Committee |
botulinum toxin thrombosed external haemorrhoids pain |
Embolism and Thrombosis Botulinum Toxins Digestive System Diseases Embolism Gastrointestinal Diseases Vascular Diseases |
Hemorrhoids Pain Botulinum Toxin Type A Intestinal Diseases Rectal Diseases Thrombosis |
Anti-Dyskinesia Agents Therapeutic Uses Cardiovascular Diseases Central Nervous System Agents Pharmacologic Actions |